首页> 外文会议>Falk Symposium >State-of-the-Art Lecture: Emerging biologic therapies
【24h】

State-of-the-Art Lecture: Emerging biologic therapies

机译:最先进的讲座:新兴的生物疗法

获取原文
获取外文期刊封面目录资料

摘要

There are a number of emerging biologic therapies for the treatment of inflammatory bowel disease including anti-tumour necrosis factor (TNF) agents (adalimumab, certolizumab, pegol, CDP571, etanercept, onercept), anti-selective adhesion molecule agents (natalizumab, MLN-02), and miscellaneous agents such as ABT-874 (anti-interleukin 12 antibody), sargramonstim (GMCSF), and visilizumab (anti-CD3 antibody). This chapter will review the results of clinical trials with these agents in patients with Crohn's disease (CD) and ulcerative colitis (UC).
机译:有许多新兴的生物疗法用于治疗炎性肠病,包括抗肿瘤坏死因子(TNF)剂(Adalimalab,Certolizumab,Pegol,CDP571,entanercept,onercept),抗选择性粘附分子剂(NaTalizumab,MLN- 02)和诸如ABT-874(抗白细胞介素12抗体),Sarramstim(GMCSF)和Visilizumab(抗CD3抗体)等杂种试剂。本章将审查克罗恩病(CD)和溃疡性结肠炎(UC)患者中具有这些药剂的临床试验结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号